home / stock / rfl / rfl news


RFL News and Press, Rafael Holdings Inc. Class B From 06/21/21

Stock Information

Company Name: Rafael Holdings Inc. Class B
Stock Symbol: RFL
Market: NYSE
Website: rafaelholdings.com

Menu

RFL RFL Quote RFL Short RFL News RFL Articles RFL Message Board
Get RFL Alerts

News, Short Squeeze, Breakout and More Instantly...

RFL - Rafael Holdings Announces Strategic Merger with Rafael Pharmaceuticals to Form a Focused Late-Stage Clinical Oncology Company

Rafael Holdings Announces Strategic Merger with Rafael Pharmaceuticals to Form a Focused Late-Stage Clinical Oncology Company Rafael Pharmaceuticals' lead asset, CPI-613® (devimistat), is in Phase 3 clinical trials in pancreatic cancer and relapsed or refractory acute myelo...

RFL - Rafael Holdings reports FQ3 results

Rafael Holdings (RFL): FQ3 GAAP EPS of -$0.15.Revenue of $1M (-18.0% Y/Y)Press Release For further details see: Rafael Holdings reports FQ3 results

RFL - Rafael Holdings adds three new members to board

Rafael Holdings (RFL) announces the appointment of three senior biopharmaceutical leaders to the company's board of directors.The new board members are Ameet Mallik, Chief Executive Officer of Rafael Holdings; Shannon Thyme Klinger, Chief Legal Officer of Moderna (MRNA); and Ma...

RFL - Rafael Holdings Appoints Three Highly Experienced Biopharmaceutical Leaders to its Board of Directors

Rafael Holdings Appoints Three Highly Experienced Biopharmaceutical Leaders to its Board of Directors Ameet Mallik, Chief Executive Officer of Rafael Holdings, Shannon Thyme Klinger, Chief Legal Officer of Moderna, Inc., and Mark McCamish, M.D., Ph.D., President and Chief Execut...

RFL - Rafael Holdings Reports Third Quarter Fiscal Year 2021 Results

Rafael Holdings Reports Third Quarter Fiscal Year 2021 Results PR Newswire NEWARK, N.J. , June 14, 2021 /PRNewswire/ -- Rafael Holdings, Inc., (NYSE: RFL), reported revenue of $1.0 million and a loss per share of $0.15 for the third quarter of its 20...

RFL - ASCO 2021: A Plethora Of Cancer Therapeutic Investment Ideas

ASCO is a very important cancer clinical research meeting. We identified 70 smid-cap cancer companies presenting updated clinical data at ASCO21. 13 companies' value increased by over 10% with ASCO21 info release thus far. PDSB is an early ASCO21 mover, with its HPV vaccine ca...

RFL - Rafael Pharmaceuticals to Present New Pancreatic Cancer and Biliary Tract Cancer Data featuring CPI-613® (Devimistat) at the American Society of Clinical Oncology (ASCO) 2021 Virtual Scientific Program

CRANBURY, N.J., May 26, 2021 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based therapeutics, today announced that it will present two posters at the 2021 American Society o...

RFL - Tracking Kahn Brothers Portfolio - Q1 2021 Update

Kahn Brothers’ 13F portfolio value increased from $579M to $646M this quarter. Stakes in VOXX International and BlackBerry were decreased during the quarter. The portfolio continues to be very concentrated with the top five positions accounting for ~45% of the 13F holdings....

RFL - Old West Investment Management Q1 2021 Investor Letter

Old West manages long only and long/short investment strategies based upon the companies that we uncover through our simple yet sound investment process. We outperformed the market by a wide margin, with our LP’s up on average 25% net of fees and our separate accounts up over 3...

RFL - Rafael Holdings Announces Inducement Grant Under NYSE Rule 303A.08

Rafael Holdings Announces Inducement Grant Under NYSE Rule 303A.08 PR Newswire NEWARK, N.J. , April 16, 2021 /PRNewswire/ -- Rafael Holdings, Inc., (NYSE: RFL), today announced that on April 15, 2021 it made a grant to William Conkling of options to purch...

Previous 10 Next 10